NICE recommends NHS use of Vosevi in chronic hepatitis C.- AbbVie.

In final guidelines, NICE has given approval for the use of Vosevi (sofosbuvir + velpatasvir + voxilaprevir), from Gilead Sciences, as an option for treating chronic hepatitis C in adults, only if it is used as a 12-week treatment regimen, for patients without cirrhosis or with compensated cirrhosis, on the back of clinical data showing high cure rates, and the company provides the drug at the same price or lower than that agreed with the Commercial Medicines Unit.

The approval is partlly based on clinical data from two Phase III clinical trials, involving around 750 HCV patients without cirrhosis or with mild cirrhosis, showed that 96-97 percent of those who received Vosevi had no virus detected in the blood 12 weeks post treatment. The company's economic evidence is limited to people who have had direct-acting antivirals (DAA) (genotypes 1�6) and people with genotype 3 hepatitis C who have not had DAA before. This reflects the groups with the highest unmet clinical need. Cost-effectiveness estimates for sofosbuvir�velpatasvir�voxilaprevir are within what NICE usually considers acceptable.

Comment: The recommended dose is 1 tablet taken orally once daily. Each tablet contains 400 mg sofosbuvir, 100 mg velpatasvir and 100 mg voxilaprevir. Treatment duration is 8 or 12 weeks depending on cirrhosis status and whether the person has had previous treatment with direct-acting antivirals.